Research
Energy balance
Tirzepatide facilitated an average 18.5% weight loss (>46 pounds) in overweight and obese patients with type 1 diabetes at 1 year.
Practitioners may consider tirzepatide as an effective option for weight management in this patient population.
StrongSupportsmedium confidence
In this pilot (off label) study, we conclude that tirzepatide facilitated an average 18.5% weight loss (>46 pounds) and improved glucose control in OW/OB patients with T1D at 1 year.
Why this rating
Based on study design from abstract.
Source
Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes
Satish K. Garg et al. · Diabetes Technology & Therapeutics · 2024
cohort · n=62Cited 57×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →